Esperion Therapeutics tumbles after stock offering launch

Esperion Therapeutics

07/10/2025 21:50

** Shares of Esperion Therapeutics ESPR.O down 18.1% to $2.53 post-market after follow-on offering commenced

** Ann Arbor, Michigan-based Esperion announces proposed stock offering; deal size not disclosed

** Piper Sandler and Cantor Fitzgerald are joint bookrunners

** On Fri, Esperion said it reached a settlement with India-based Dr. Reddy’s Laboratories that will prevent the latter from selling generic versions of its cholesterol drugs Nexletol and Nexlizet in the U.S. before April 2040

** Esperion plans to use net offering proceeds primarily to fund commercialization efforts for both cholesterol drugs, for R&D of current or additional pipeline candidates, per the prospectus

** ESPR shares on Tues finished down 1% at $3.09, trimming YTD gain to ~40%. Stock has nearly tripled over the last 6 months

** With ~201.6 mln shares outstanding, co has roughly $620 mln market cap

** Of 8 analysts covering ESPR, recommendation breakdown is 5 "strong buy" or "buy", 2 "hold" and 1 "sell"; median PT is $4, per LSEG

 (Lance Tupper is a Reuters market analyst. The views expressed are his own)

 ((lance.tupper@tr.com 1-646-279-6380))